JP2019515035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515035A5 JP2019515035A5 JP2019508162A JP2019508162A JP2019515035A5 JP 2019515035 A5 JP2019515035 A5 JP 2019515035A5 JP 2019508162 A JP2019508162 A JP 2019508162A JP 2019508162 A JP2019508162 A JP 2019508162A JP 2019515035 A5 JP2019515035 A5 JP 2019515035A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- snp
- subject
- kras
- single nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022163987A JP2022179694A (ja) | 2016-04-27 | 2022-10-12 | Ｋｒａｓバリアントがん患者の免疫ベースの処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328548P | 2016-04-27 | 2016-04-27 | |
| US62/328,548 | 2016-04-27 | ||
| PCT/US2017/029938 WO2017189906A1 (en) | 2016-04-27 | 2017-04-27 | Immune-based treatment of kras-variant cancer patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022163987A Division JP2022179694A (ja) | 2016-04-27 | 2022-10-12 | Ｋｒａｓバリアントがん患者の免疫ベースの処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515035A JP2019515035A (ja) | 2019-06-06 |
| JP2019515035A5 true JP2019515035A5 (https=) | 2020-06-11 |
Family
ID=59215945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508162A Pending JP2019515035A (ja) | 2016-04-27 | 2017-04-27 | Ｋｒａｓバリアントがん患者の免疫ベースの処置 |
| JP2022163987A Pending JP2022179694A (ja) | 2016-04-27 | 2022-10-12 | Ｋｒａｓバリアントがん患者の免疫ベースの処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022163987A Pending JP2022179694A (ja) | 2016-04-27 | 2022-10-12 | Ｋｒａｓバリアントがん患者の免疫ベースの処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200325234A1 (https=) |
| EP (1) | EP3449015A1 (https=) |
| JP (2) | JP2019515035A (https=) |
| CN (1) | CN109790581A (https=) |
| WO (1) | WO2017189906A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018283314B2 (en) | 2017-06-15 | 2025-05-29 | Miradx | Biomarkers for predicting tumor response to and toxicity of immunotherapy |
| EA202092147A1 (ru) * | 2018-03-13 | 2021-03-04 | Иннейт Фарма | Лечение рака головы и шеи |
| AU2020289484A1 (en) * | 2019-06-07 | 2021-12-23 | Emory University | KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4988617A (en) | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
| WO1989010414A1 (en) | 1988-04-28 | 1989-11-02 | Robert Bruce Wallace | AMPLIFIED SEQUENCE POLYMORPHISMS (ASPs) |
| US4988167A (en) | 1988-08-10 | 1991-01-29 | Fergason James L | Light blocking and vision restoration apparatus with glint control |
| US5118801A (en) | 1988-09-30 | 1992-06-02 | The Public Health Research Institute | Nucleic acid process containing improved molecular switch |
| CA2044591C (en) | 1989-02-13 | 2002-08-13 | James Langham Dale | Detection of a nucleic acid sequence or a change therein |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5302509A (en) | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
| US5494810A (en) | 1990-05-03 | 1996-02-27 | Cornell Research Foundation, Inc. | Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
| CA2153387A1 (en) | 1993-01-07 | 1994-07-21 | Hubert Koester | Dna sequencing by mass spectrometry |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| IL108159A (en) | 1993-12-23 | 1998-02-08 | Orgenics Ltd | Apparatus for separation, concentration and detection of target molecules in liquid sample |
| EP0754240B1 (en) | 1994-02-07 | 2003-08-20 | Beckman Coulter, Inc. | Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis |
| AU710425B2 (en) | 1995-12-18 | 1999-09-23 | Washington University | Method for nucleic acid analysis using fluorescence resonance energy transfer |
| EP2332958B1 (en) | 1996-02-09 | 2016-04-20 | Cornell Research Foundation, Inc. | Detection of nucleic and sequence differences using the ligase detection reaction with addressable arrays |
| EP1736554B1 (en) | 1996-05-29 | 2013-10-09 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US5866336A (en) | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6506594B1 (en) | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| US9090693B2 (en) * | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| EP2183386A1 (en) | 2007-05-31 | 2010-05-12 | Yale University | A genetic lesion associated with cancer |
| US20140065615A1 (en) * | 2011-03-21 | 2014-03-06 | Yale University | The KRAS Variant and Tumor Biology |
| JP6238459B2 (ja) * | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| CN103547683A (zh) * | 2012-03-22 | 2014-01-29 | 耶鲁大学 | Kras突变和肿瘤生物学 |
| EP2981281B1 (en) * | 2013-04-03 | 2020-07-15 | IBC Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2014193937A1 (en) * | 2013-05-31 | 2014-12-04 | Yale University | The kras variant and response to cancer therapy |
-
2017
- 2017-04-27 WO PCT/US2017/029938 patent/WO2017189906A1/en not_active Ceased
- 2017-04-27 JP JP2019508162A patent/JP2019515035A/ja active Pending
- 2017-04-27 US US16/096,316 patent/US20200325234A1/en not_active Abandoned
- 2017-04-27 EP EP17733169.1A patent/EP3449015A1/en not_active Withdrawn
- 2017-04-27 CN CN201780039884.3A patent/CN109790581A/zh active Pending
-
2022
- 2022-10-12 JP JP2022163987A patent/JP2022179694A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer | |
| Botticelli et al. | The sexist behaviour of immune checkpoint inhibitors in cancer therapy? | |
| Kang et al. | Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic | |
| Concha-Benavente et al. | Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer | |
| JP7564122B2 (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| WO2019094392A1 (en) | Cancer biomarkers and methods of use thereof | |
| US20240344138A1 (en) | Targeted therapies in cancer | |
| CN107923918A (zh) | 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法 | |
| US20220175787A1 (en) | Patient selection for enhancement of anti-tumor immunity in cancer patients | |
| Nakashima et al. | Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells | |
| TW201900193A (zh) | 用於癌症治療之生物標記物 | |
| Al Bakir et al. | Clonal driver neoantigen loss under EGFR TKI and immune selection pressures | |
| Church et al. | Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma | |
| JP2022519649A (ja) | がんの診断および治療方法 | |
| WO2017205213A1 (en) | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer | |
| Wang et al. | CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors | |
| JP2019515035A5 (https=) | ||
| Magyari et al. | Gender effects on treatment response to interferon‐beta in multiple sclerosis | |
| Someya et al. | Combined chemoradiotherapy and programmed cell death‐ligand 1 blockade leads to changes in the circulating T‐cell receptor repertoire of patients with non‐small‐cell lung cancer | |
| EP3612639A1 (en) | Biomarker for small cell lung cancer therapy | |
| CA2990299C (en) | Method for inducing early t memory response with short peptides anti-tumor vaccine | |
| Guo et al. | Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): halfway report | |
| Xu et al. | Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study | |
| Palermo et al. | Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients | |
| Malecki et al. | Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus |